Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Dianthus Therapeutics (DNTH) Accounts Payables: 2017-2024

Historic Accounts Payables for Dianthus Therapeutics (DNTH) over the last 6 years, with Dec 2024 value amounting to $4.6 million.

  • Dianthus Therapeutics' Accounts Payables fell 11.45% to $6.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $6.7 million, marking a year-over-year decrease of 11.45%. This contributed to the annual value of $4.6 million for FY2024, which is 75.44% up from last year.
  • Per Dianthus Therapeutics' latest filing, its Accounts Payables stood at $4.6 million for FY2024, which was up 75.44% from $2.6 million recorded in FY2023.
  • Dianthus Therapeutics' 5-year Accounts Payables high stood at $4.6 million for FY2024, and its period low was $1.2 million during FY2022.
  • Over the past 3 years, Dianthus Therapeutics' median Accounts Payables value was $2.6 million (recorded in 2023), while the average stood at $2.8 million.
  • Data for Dianthus Therapeutics' Accounts Payables shows a peak YoY surged of 123.65% (in 2023) over the last 5 years.
  • Yearly analysis of 3 years shows Dianthus Therapeutics' Accounts Payables stood at $1.2 million in 2022, then skyrocketed by 123.65% to $2.6 million in 2023, then soared by 75.44% to $4.6 million in 2024.